anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The time-equivalent, stretching movements will serve as the placebo exercise condition in this proposed study. Previous research has shown that stretching could reduce attrition and patient dissatisfaction and better ensure allocation concealment. Following baseline measures, a student will demonstrate the use of a Polar United fitness watch and stretching movements via zoom from week 3 to week 5. Starting on week 3, participants will perform the prescribed stretching exercise 3 times a week, maintaining heart rate below 40% of heart rate reserve during exercise.
Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve acceptable serum levels. Erythromycin is largely bound to plasma proteins, and the freely dissociating bound fraction after administration of erythromycin base represents 90 percent of the total erythromycin absorbed. After absorption, erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid, but the passage of the drug across the blood-brain barrier increases in meningitis. The drug is excreted in human milk. The drug crosses the placental barrier, but fetal plasma levels are low. Erythromycin is not removed by peritoneal dialysis or hemodialysis.

In the presence of normal hepatic function erythromycin is concentrated in the liver and is excreted in the bile; the effect of hepatic dysfunction on biliary excretion of erythromycin is not known. After oral administration, less than 5 percent of the administered dose can be recovered in the active form in the urine.

The enteric coating of pellets in Erythromycin Delayed release Capsules, USP protects the erythromycin base from inactivation by gastric acidity. Because of their small size and enteric coating, the pellets readily pass intact from the stomach to the small intestine and dissolve efficiently to allow absorption of erythromycin in a uniform manner. After administration of a single dose of a 250 mg Erythromycin Delayed-release Capsule, USP, peak serum levels in the range of 1.13 to 1.68 mcg/mL are attained in approximately 3 hours and decline to 0.30 to 0.42 mcg/mL in 6 hours. Optimal conditions for stability in the presence of gastric secretion and for complete absorption are attained when erythromycin is taken on an empty stomach.
The callikrein inactivator is isolated from the waste fractions obtained during the production of insulin from the pancreas of animals, e.g. cattle and pigs, by known methods for the isolation of callikrein inactivator from extracts of animal organs containing the callikrein inactivator.  These waste fractions are (a) the precipitate formed by neutralization of the acidic alcoholic pancreas extract, e.g. with ammonia to pH 7 to 8 and (b) the mother liquor remaining after the separation of crude insulin from the aqueous solution with 20 to 25% of sodium chloride.  The precipitate of (a) may be extracted with aqueous methanol containing calcium chloride or manganous chloride, separating the extract and precipitating the callikrein inactivator by acetone in the presence of kieselguhr. After washing with acetone, the callikrein inactivator is extracted with water and may be further purified by precipitating waste proteins by sulphosulphosalicylic acid, followed by removal of excess precipitating agent by ion exchanger.  Specifications 783,316, 886,989 and 916,932 are referred to.
Indacaterol 300 μg once a day (o.d.) delivered via single dose dry powder inhaler (SDDPI). Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
This entire protocol involves procedures that are standard care and will randomize subjects to of one two routine care procedures. Patients needing maxillary sinus augmentation will be enrolled. There will be two subject groups in this study both of which will randomized to one of two standard care procedures. No risk or benefit is expected from being assigned to either group as both procedures are both standard care. In both groups a bone sample (core) will be obtained as a by-product of implant placement. Bone will not be extracted solely for research purposes, the bone sample attained for research will only be from bone left over after the SOC implant placement.

Allocation of subjects into test group or control group will be based on numbers drawn from a stack of sealed envelopes.
Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and then on day 1 of subsequent cycles. Beginning in cycle 2, patients also receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Paranasal concavity is esthetically displeasing and interferes with the overall outline of the face. Paranasal augmentation with alloplastic implants is a minimally invasive procedure with significant esthetic effects for paranasal concavity. When fixing the implants, the screws should be placed on the nasofrontal column, but are occasionally mispositioned on the anterior wall of the maxillary sinus. Here, the authors introduce a case of paranasal augmentation in which the self-tapping screw accidentally penetrated through the implant, broke through the anterior and medial walls of the maxillary sinus, and entered the nasal cavity. The screw was located by a computed tomography scan and was successfully removed under a nasal endoscope. The causes of this intraoperative complication were analyzed, emergent management was introduced, and a further preventive strategy was proposed.
BACKGROUND: Cranioplasty is a relatively simple neurosurgical procedure, and common complications of cranioplasty include dural tears, CSF leakage, infection, epilepsy, epidural hematoma and bone flap resorption. Intracerebral hemorrhage as a complication of cranioplasty is rare, and it is often fatal. The report describes one case of delayed severe intracerebral and intraventricular hemorrhage after an uneventful cranioplasty.
CASE PRESENTATION: A previously healthy 29-year-old man was admitted to our hospital with a traumatic left frontotemporoparietal acute subdural hematoma, an emergency decompressive craniectomy with clot removal was performed. Four months after the surgery, cranioplasty was performed with a titanium mesh, the surgery was uneventful. Six hours after the operation, a CT scan demonstrated no bleeding or edema. In the following 2 days after cranioplasty, the patient did not have any neurological deficits, normal blood pressure was recorded every day, no trauma occurred, and routine laboratory test results were within normal limits. However, on the third day after cranioplasty, the patient suffered a sudden severe headache while playing games on his mobile phone, and then rapidly fell into deep coma; both pupils were fixed and dilated at 5 mm with no response to light. An immediate CT scan revealed a massive intracerebral hematoma and intraventricular hematoma on the left side, and the midline shifted to the right side. Therefore, an ipsilateral decompressive craniectomy was performed with evacuation of the hematoma; the obvious bleeding point was not identified, and no obvious vascular abnormalities were found during the operation. A CT scan on day 3 after reoperation revealed successful decompression, and CT angiography showed no vascular abnormalities. Despite all treatment measures, the patient did not regain consciousness, his neurological situation did not improve after the operation, and the patient lived in a vegetative state.
CONCLUSION: Although intracerebral and intraventricular hemorrhage after cranioplasty is extremely rare, it is often fatal. Aside from hyperperfusion and cerebral autoregulation dysfunction, traction injuries to the fragile vessels due to posttraumatic angiogenesis may also be one of the key factors of complications after cranioplasty.
The safety and effectiveness of BECONASE AQ Nasal Spray have been established in children aged 6 years and above through evidence from extensive clinical use in adult and pediatric patients. The safety and effectiveness of BECONASE AQ Nasal Spray in children below 6 years of age have not been established.

Controlled clinical studies have shown that intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of HPA axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The long-term effects of this reduction in growth velocity associated with intranasal corticosteroids, including the impact on final adult height, are unknown. The potential for “catch-up” growth following discontinuation of treatment with intranasal corticosteroids has not been adequately studied. The growth of pediatric patients receiving intranasal corticosteroids, including BECONASE AQ Nasal Spray, should be monitored routinely (e.g., via stadiometry). The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained and the risks/benefits of treatment alternatives. To minimize the systemic effects of intranasal corticosteroids, including BECONASE AQ Nasal Spray, each patient should be titrated to the lowest dose that effectively controls his/her symptoms.

In a double-blind, controlled trial, 100 children between the ages of 6 and 9½ years with allergic rhinitis were randomized to receive aqueous intranasal beclomethasone dipropionate 168 mcg twice daily or placebo for 1 year. As measured by stadiometry, children who received beclomethasone dipropionate grew more slowly than those who received placebo. A difference in mean change in height was observed within 1 month of drug initiation. At the end of 12 months, the beclomethasone dipropionate-treated group had a growth velocity on average of 4.75 cm/year compared to 6.20 cm/year in the placebo group (P<0.01). While the placebo group had an expected distribution of growth velocity, approximately 50% of the beclomethasone dipropionate-treated children grew below the 10th percentile.

In children 7.3 years of age, the mean age of children in this study, the range for expected growth velocity is: boys − 3rd percentile = 4.1 cm/year, 50th percentile = 5.8 cm/year, and 97th percentile = 7.5 cm/year; girls − 3rd percentile = 4.3 cm/year, 50th percentile = 5.9 cm/year, and 97th percentile = 7.5 cm/year. The potential reversibility of the reduction in growth velocity was not studied. No significant differences were observed between the 2 groups for mean basal plasma cortisol or ACTH-stimulated plasma cortisol levels.
Compositions containing an anti-inflammatory proteolytic enzymatic complex (I), and a vasculotropic mixture (II) of a Ruscus Aculeatus L extract and >=1 Vitamin P factor, are new. The enzymatic complex (I) is pref. isolated from the pancreas and has chymotripsic anc trypsic activity, esp. 15000U of chymotrypsin and 10500U of trypsin (NF units). The extracts used in (II) are pref. sterolic heterosides prepd. from rhizomes of R. Aculeatus. The vitamin P factor used in (II) may be a chalconised and alkylated water soluble derivative of flavonic glucosides, esp. hesperidin-methyl-chalcone. Pref. presentation of the compsn is a tablet with (I) in the core and enteric coated and (II) in an outer layer. Used as anti-inflammatories and vaculotropes in human and veterinary medicine, esp. for haemorrhoidal crises, post-traumatic vascular disorders or oedema, in gynaecology for pelvic congestion and pain, and various disorders associated with oral and/or intra/uterine contraception. Synergism exists between (I) and (II).
Magnesium Sulfate in Water for Injection is a sterile, nonpyrogenic solution of magnesium sulfate heptahydrate in water for injection. May contain sulfuric acid and/or sodium hydroxide for pH adjustment. The pH is 4.5 (3.5 to 6.5). It is available in 4% and 8% concentrations. See HOW SUPPLIED section for the content and characteristics of available dosage forms and sizes. 

Magnesium sulfate, USP heptahydrate is chemically designated MgSO 4 • 7H 2O, colorless crystals or white powder freely soluble in water. 

Water for injection, USP is chemically designated H 2O. 

The flexible container is fabricated from a specially formulated non-plasticized, film containing polypropylene and thermoplastic elastomers ( freeflex ® bag). The amount of water that can permeate from the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the flexible container can leach out certain of the container’s chemical components in very small amounts within the expiration period. The suitability of the container material has been confirmed by tests in animals according to USP biological tests for plastic containers. Exposure to temperatures above 25ºC/77ºF during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
The invention relates to a tissue regenerating agent. The inventive agent is used in the field of medicine and in the pharmaceutical field. The aim of the invention is to provide a novel agent for the regeneration of tissue. To this end, a fusion protein is produced that induces the cells of damaged tissue to temporarily proliferate, thereby effecting the regeneration of the tissue. The inventive tissue regenerating agent comprises an agent that contains a fusion protein derived from a protein or a peptide sequence that effects the uptake in the cells, and a protein that induces the proliferation of cells. Preferably, a fusion protein derived from the viral VP22 protein and the SV40 T antigen is used.
PURPOSE: To explore final-year medical students' perceptions of sleep education during medical school to inform the development of a sleep curriculum.
METHODS: Year 6 medical students on their final general practice placement in 2020 were invited to complete an online survey including questions regarding sleep education recalled during the medical programme.
RESULTS: Responses were received from 51/71 (72 %) students. Main learning topics recalled by participants were sleep apnoea (83 %), sleep physiology (71 %), and snoring (69 %). Education in other topics was reported by <65 % of students. Priority topics for students were treating common sleep disorders, taking a sleep history, and navigating shift work.
CONCLUSIONS: Whilst the majority of students recalled education on specific topics, many had little awareness of education relating to sleep assessment, insomnia, or shift work. Sleep education in the curriculum needs more emphasis and reinforcement given sleep's relevance across many domains of health and morbidity. We propose that an identifiable sleep curriculum is required to ensure medical students have the necessary core education regarding sleep and sleep disorders both for patients and themselves. Further, we believe this is possible to achieve in a short timeframe within the constraints of an existing curriculum and propose some creative solutions.
A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health \& Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing "moderate or worse" pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff.
ABSTRACT OF THE DISCLOSURE         Processes are provided for producing novel esters and salts thereof with certain pharmaceutically acceptable acids, e.g. non-toxic strong inorganic acids or organic acids. The novel compounds have the formula                       I     in which R1 and R2 represent the same or different substituents, and each represents hydrogen or lower alkyl;  A represents a carbon chain having from 5 to 8 carbon atoms, a carbon chain having 5 to 8 carbon atoms in which an oxygen atom is substituted for a methylene group, a carbon atom chain having 5 to 8 carbon atoms in which a sulphur atom is substituted for a methylene group, or the grouping   represents a bicyclic system containing from 5 to 10 carbon atoms, or a bicyclic system containing from 4 to 9 carbon atoms, or a bicyclic system containing from 4 co 9 carbon atoms in which an oxygen atom is substitu-ted for a methylene group, or a bicyclic system containing from 4 to 9 carbon atoms in which a sulphur atom is substituted for a methylene group, or the grouping   represents a spirocyclic system containing from 7 to 10 carbon atoms;  and R3 represnts hydrogen, lower alkyl selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl tert-butyl, pentyl, neopentyl and hexyl and the corresponding isomers, and halogen substituted lower alkyl selected from chloromethyl, trichloromethyl, trifluoromethyl and 2,2,2-trichloroethyl and similar radical, and unsubstituted aryl and aralkyl, the aryl part of which is selected from phenyl, 2-fluorophenyl, 3-fluoro-phenyl, 4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,4,6-trichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-isopropyloxyphenyl, 2-tolyl, 3-tolyl, 4-tolyl, 1-naphthyl, and 2-naphthyl.  These compounds are valuable in human and veterinary prac-tice and are absorded efficiently when given orally and are non-toxic when given parenterally.  After the absorption the esters are converted to the corresponding penicillanic acids by enzymatic hydrolysis.  Furthermore, these esters and the salts specified above are chemically more stable than the corresponding free acids.  A specific example of such ester is bis(6-[(hexahydro-azepin-1-yl)-methyleneamino]-penicillanoyloxy)-methane.
BACKGROUND- Most of the models for T2DM risk assessment exist for use in medical settings and include data which is commonly unavailable to dentists. To overcome the limitation of applicability of existing diabetes-risk assessment tools in dental settings, the Diabetes Risk Assessment in Dentistry Score (DDS) was developed utilizing measures routinely available to dentists. It has been developed and validated in a German population and found to perform broadly at par with those validated for use in medical settings. RATIONALE-Models developed in a specific population need to be validated in other populations before they can be adopted. The DDS screening tool has not been validated in Indian population till date. OBJECTIVES- To assess performance of DDS screening tool in predicting the risk of prediabetes and type 2 diabetes mellitus among individuals seeking dental consultation in Indian population. METHODS-The study participants will include individuals seeking dental consultation at a university teaching hospital in India. All participants will undergo DDS risk-assessment followed by measurement of serum HbA1c levels to establish diagnosis of health, prediabetes or undiagnosed T2DM. EXPECTED OUTCOMES-It is expected that the DDS screening model performs well in Indian population, with scope for incorporation of the model during regular dental visits.
OBJECTIVE: Cancer survivors have unique healthcare needs. An important consideration for survivorship is chronic diseases and health risk factors. The purpose of this study is to describe demographics, risk factors, and comorbid health conditions in adult cancer survivors.
METHOD: We analyzed 2019 Arizona Behavioral Risk Factor Surveillance System data to compare cancer survivors to non-cancer survivors (aged 18 or older) to assess differences between the two populations. Adjusted and unadjusted population-based estimates and 95% confidence intervals were calculated, and multivariable logistic regression models were performed.
RESULTS: Eight thousand nine-hundred and twenty (8920) respondents (1007 survivors; 7913 non-cancer survivors) were included. Compared to non-cancer survivors, cancer survivors were more likely to be female, 65 years and older, non-Hispanic white, veterans, and less likely to be employed. Survivors had higher rates of coronary heart disease, stroke, chronic obstructive pulmonary disease, kidney disease, hypertension, arthritis, multiple chronic conditions, being overweight, and being a former smoker. Survivors were more likely to report fair/poor health than non-cancer survivors.
DISCUSSION: These findings can be used by healthcare and public health practitioners to evaluate the programmatic efforts and resources, implement targeted interventions toward cancer survivors, and improve health and quality of life.
The present invention relates to a scorpion analgetic anti-tumor Val-Arg-Gly peptide and its preparation method. The scorption analgetic anti-tumor Val-Arg-Gly peptide is from scorpion or scorpion venom. The gene of scorpion analgetic anti-tumor Val-Arg-Gly peptide and its partial fragment, derivative and analog and can be obtained by using scorpion or utilizing chemical synthesis. The scorpion analgetic anti-tumor Val-Arg-Gly peptide or its partial fragment or its derivative and analog can be prepared by using chemical synthesis production process. The scorpion analgetic anti-tumor Val-Arg-Gly peptide or its partial fragment or its derivative and analog can be prepared by gene engineering technology. They can be used as analgetic anti-tumor medicine.
Jaundice is a symptom of high blood bilirubin levels affecting about 80% of neonates. In neonates fed with breast milk, jaundice is particularly prevalent and severe, which is likely multifactorial. With the development of genomics and metagenomics, a deeper understanding of the neonatal gut microbiota has been achieved. We find there are accumulating evidence to indicate the importance of the gut microbiota in the mechanism of jaundice. In this paper, we present new comprehensive insight into the relationship between the microbiota and jaundice. In the new perspective, the gut is a crucial crossroad of bilirubin excretion, and bacteria colonizing the gut could play different roles in the excretion of bilirubin, including Escherichia coli as the main traffic jam causers, some Clostridium and Bacteroides strains as the traffic police, and most probiotic Bifidobacterium and Lactobacillus strains as bystanders with no effect or only a secondary indirect effect on the metabolism of bilirubin. This insight could explain why breast milk jaundice causes a longer duration of blood bilirubin and why most probiotics have limited effects on neonatal jaundice. With the encouragement of breastmilk feeding, our perspective could guide the development of new therapy methods to prevent this side effect of breastfeeding.